| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
4,847 |
3,310 |
$7.39M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
20,234 |
15,380 |
$5.92M |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
1,148 |
795 |
$784K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
1,907 |
1,446 |
$762K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
10,736 |
10,481 |
$684K |
| 92134 |
|
19,255 |
18,618 |
$674K |
| J9035 |
Injection, bevacizumab, 10 mg |
6,783 |
4,698 |
$492K |
| 92250 |
|
4,606 |
4,474 |
$201K |
| 92235 |
|
1,805 |
1,786 |
$157K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
3,328 |
3,281 |
$150K |
| 67228 |
|
206 |
182 |
$68K |
| 92226 |
|
1,532 |
902 |
$61K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
905 |
905 |
$59K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
433 |
428 |
$39K |
| J0177 |
Injection, aflibercept hd, 1 mg |
14 |
13 |
$23K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
359 |
353 |
$18K |
| 92202 |
|
1,015 |
1,011 |
$15K |
| J3490 |
Unclassified drugs |
17 |
13 |
$12K |
| 92201 |
|
353 |
340 |
$8K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
138 |
137 |
$4K |
| 92225 |
|
54 |
29 |
$3K |
| 76512 |
|
51 |
48 |
$2K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
16 |
15 |
$2K |